SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for WM2032-01-0010

WM2032 Viable Cells

Overview

Description:	WM2032 Viable Cells - WM2032-01-0010
Item No.:	WM2032-01-0010
Size:	10 x 1 million cells
Applications:	Cellular Assay, Functional Assay, IHC, WB
Origin:	Human

Product Details

Background:	WM2032 is a metastatic human melanoma cell line that was established from a lymph node metastatic site of a patient. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. WM2032 cells match WM3000. These cells produce xenograft tumors when injected into immunocompromised mice.
Synonyms:	Melanoma, patient derived tumor, tumor models, skin cancer, xenograft
Species of Origin:	Human

Target Details

Purity/Specificity:	Cells are sterile, validated by short tandem repeat profiling, and are tested as negative for mycoplasma. It is recommended that cell lines are tested for mycoplasma contamination and short tandem repeat (STR) profiling every 10 passages or each time a frozen seed stock is made. See cell culture protocol for additional details.
Relevant Links:	• Cell Line EULA • Melanoma Cell Culture Protocol

Application Details

Suggested Applications:	Cellular Assay, Functional Assay, IHC, WB (Based on references)

Application Note:	The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Cell Line Data

Cell Line:	Human Melanoma
Product Type:	Viable Cells
Cell Viability:	Yes
Stage:	LN Metastasis
BRAF:	WT
CDK4:	WT
C-Kit:	WT
N-RAS:	Q61R
PTEN:	WT
Paired:	Yes
Medium:	Tumor Specialized Media with 2% HI-FBS
Sub-culture:	Cells should be maintained between 30 – 95% confluence in tumor specialized medium with 2% FBS; split cultures 1:4 every week using 0.25% trypsin/EDTA.
Incubation:	36°C with 5% CO2

Formulation

Physical State:	Frozen Cell Suspension
Concentration:	1.0 million cells/mL Count By Hemocytometer
Buffer:	None
Preservative:	None
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice

Storage Condition:	Cells are frozen with 90% FBS/10% DMSO solution at about 10x10^6 cells/ml. Store vial in liquid nitrogen upon arrival.
Expiration:	Expiration date is two (2) years from date of receipt.

Images



Flask
Human melanoma tumor cells with known gene mutations, disease stage, STR, and RPPA profiling

Viable cell growth
Established WM2032 viable cell growth in culture using appropriate Tumor Specialized Media with 2%FBS.



Viable cell growth
Established WM2032 viable cell growth in culture using appropriate Tumor Specialized Media with 2%FBS.

References

- Wei BR et al. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. *Mol Cancer Ther.* (2020)
- Qian L, Chen K, Wang C, Chen Z, Meng Z, Wang P. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine. *Clin Cancer Res.* (2020)
- Yin C et al. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. *Cell.* (2019)

Disclaimer